京大：iPS免疫細胞をがん患者に移植（動画）：
Kyoto University: Transplanting iPS immune cells into cancer patients:
京都大学：将 iPS 免疫细胞移植到癌症患者中：
ー京大などが治験開始ー
京都大
国立がん研究センター11月11日「iPS細胞からつくった免疫細胞を卵巣がんの患者に移植した」と発表した。
iPS細胞を使ったがん治療：
iPS細胞を使ったがん治療は、千葉大などのチームに続き2件目。
今回は安全性や副作用を調べるのが主な目的の治験で、今のところ患者に拒絶反応などは起きていない。
卵巣がんの患者：
患者は、国立がん研究センター東病院で受診している50代女性。
- 患者は卵巣がんを再発、
- がん細胞が腹膜にも散らばっており、
- 有効な治療法がない状態だった。
iPSナチュラルキラー細胞を注射：
京大は、iPS細胞からつくった免疫細胞のナチュラルキラー細胞計数千万個を作製した。
9月に3回、患部に近い腹腔内に注射した。
免疫細胞が、がん細胞を攻撃する働きに期待する。
朝日新聞デジタル
https://www.asahi.com/articles/ASPCC528LPCCPLBJ005.html
Clinical trial starts for iPS cancer treatment
NHK WORLD-JAPAN News
Researchers in Japansay they have started a clinical trial of ovarian cancer treatment involving immune cells created from induced pluripotent stem cells, or IPS cells.
The team of researchers from the National Cancer Center Hospital East and Kyoto University’s Center for iPS Cell Research and Application
made the announcement in an online news conference on Thursday.
The iPS cells used in the treatment
are capable of developing into any kind of cell.A gene that reacts strongly to a protein unique to a certain type of ovarian cancer is inserted into iPS cells to create natural killer cells.
These NK cells
will then be injected into the ovaries of patients with this type of ovarian cancer.The team says
it does not expect the treatment to cause serious side effects because NK cells attack cancer cells but seldom affect normal ones.The team plans to conduct a clinical trial of the treatment on up to 18 patients with advanced cases of ovarian cancer that are no longer operable.
They will be administered NK cells once a week, for a maximum of four times, to determine the safety and efficacy of the treatment.
In the first case, a patient in her 50s underwent three sessions in September, and has reportedly shown no adverse reactions since then.
Dr Doi Toshihiko of the National Cancer Center Hospital East
says his team aims to confirm the safety of the therapy, and will then work out a set of rules for the storage and transportation of NK cells, as the next step toward making the treatment widely available.
In a separate development last year, another group of researchers in Japan, involving the RIKEN research institute and Chiba University,
started a clinical trial of cancer treatment using another type of immune cell — natural killer T cells, generated by iPS cells.